0.00Open1.60Pre Close0 Volume1 Open Interest12.50Strike Price0.00Turnover1297.49%IV47.57%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry1.60Extrinsic Value100Contract SizeAmericanOptions Type-0.1460Delta0.0155Gamma12.99Leverage Ratio-1.5790Theta-0.0001Rho-1.90Eff Leverage0.0026Vega
Jasper Therapeutics Stock Discussion
Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria
14 of 15 participants enrolled achieved a clinical response
10 of 12 participants in the 120mg cohort achieved a complete response
No serious adverse events; no grade 3 or higher adverse events reported
Initial data from BEACON study expected week of January 6th, 2025, including 180mg Q8W cohort
Company to host conference call and webinar today at 8:00 ...
Microsoft $Microsoft (MSFT.US)$ (office currently has nearly 400 million users, OficARPU increases after the acquisition of OpenA and Azurez-related...
No comment yet